Pharming (PHAR) Retained Earnings (2019 - 2026)

Pharming (PHAR) has 8 years of Retained Earnings data on file, last reported at $20.3 million in Q2 2026.

• Quarterly Retained Earnings fell 21.48% year-over-year to $20.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $20.3 million (down 21.48% YoY) and the FY2025 annual result came in at $28.8 million, up 13889.0% from the prior year.
• Retained Earnings slipped to $20.3 million in Q2 2026, from $23.7 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $28.8 million in Q4 2025 to a low of -$270.5 million in Q1 2022.
• A 5-year average of -$51.3 million and a median of -$225766.5 in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings plunged 108246.49% — and 2025, when it surged 13889.0%.
• Tracing PHAR's Retained Earnings over 5 years: stood at -$8.7 million in 2022, then jumped by 76.46% to -$2.1 million in 2023, then soared by 89.84% to -$209000.0 in 2024, then surged by 13889.0% to $28.8 million in 2025, then fell by 29.41% to $20.3 million in 2026.
• The last three Retained Earnings figures came in at $20.3 million (Q2 2026), $23.7 million (Q1 2026), and $28.8 million (Q4 2025), per Business Quant data.